27th Jun 2022 11:52
27 June 2022
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")
Result of AGM
Cizzle Biotechnology, the UK based diagnostics developer, announces that at the Annual General Meeting ("AGM") of the Company held earlier today, all resolutions were voted on by a poll and were passed.
The votes cast in respect of the resolutions were as follows:
Resolution | For | Against | Votes withheld | ||
Total votes | % | Total votes | % |
| |
1. That the Annual Report and Accounts for the year ended 31 December 2021 be received |
55,444,064
| 100.00% | 0 | 0.00% |
30,000
|
2. For the approval of the Directors' Remuneration Policy which takes effect immediately after the end of the AGM |
55,297,384
| 94.84% |
90,139
| 0.16% |
86,541
|
3. For the approval of the Remuneration Report set out on pages 21 to 26 of the annual report |
55,297,584
| 99.84% |
90,139
| 0.16% |
86,341
|
4. For the re-election of John Treacy as a director of the Company |
55,444,064
| 100.00% | 0 | 0.00% |
30,000
|
5. For the re-election of Nigel Lee as a director of the Company |
55,444,064
| 100.00% | 0 | 0.00% |
30,000
|
6. For the re-election of Dawn Coverley as a director of the Company |
55,409,864
| 99.94% |
34,200
| 0.06% |
30,000
|
7. For the re-appointment of PKF Littlejohn LLP as auditors to the Company.
|
55,444,064
| 100.00% | 0 | 0.00% |
30,000
|
8. Authorises the Directors to determine the remuneration of the auditors |
55,388,125
| 99.90% |
55,939
| 0.10% |
30,000
|
9. Authorises the directors to allot shares pursuant to Section 551 of the Companies Act 2006 |
54,796,868
| 99.89% |
58,814
| 0.11% |
618,382
|
10. Authorises the directors to allot equity securities pursuant to Section 570 of the Companies Act 2006 |
52,358,832
| 94.62% |
2,979,293
| 5.38% |
135,939
|
11. For the approval of the adoption of the new Articles of Association |
55,444,064
| 100.00% | 0 | 0.00% |
30,000
|
12. For the calling of general meetings on not less than 14 clear days' notice |
55,444,064
| 100.00% | 0 | 0.00% |
30,000
|
Enquiries:
Cizzle Biotechnology Holdings plc | Via IFC Advisory |
Allan Syms (Executive Chairman) |
Allenby Capital Limited | +44(0) 20 33285656 |
John Depasquale | |
Alex Brearley |
Novum Securities Limited | +44(0) 20 7399 9400 |
Colin Rowbury Jon Bellis |
IFC Advisory Limited | +44(0) 20 3934 6630 |
Tim Metcalfe | cizzle@investor-focus.co.uk |
Florence Chandler |
Notes to Editors:
About Cizzle Biotechnology
Cizzle Biotechnology is developing a blood test for the early detection of lung cancer. Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer.
For more information, please see https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.
Related Shares:
Cizzle Biotech